The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA

Pioglitazone (PIO) and glucagon-like peptide-1 (GLP-1) analogs limit infarct size (IS) in experimental models. The effects of the dipeptidyl-peptidase-IV inhibitors, which increase the endogenous levels of GLP-1, on myocardial protection, are unknown. We studied whether sitagliptin (SIT) and PIO hav...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of physiology. Heart and circulatory physiology 2010-05, Vol.298 (5), p.H1454-H1465
Hauptverfasser:	Ye, Yumei, Keyes, Kyle T, Zhang, Congfang, Perez-Polo, Jose R, Lin, Yu, Birnbaum, Yochai
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Blood Glucose - metabolism Blotting, Western Body Weight - drug effects Culture Media Cyclic AMP - metabolism Cyclic AMP-Dependent Protein Kinases - physiology Dipeptidyl-Peptidase IV Inhibitors - pharmacology Effects Eicosanoids - metabolism Glucagon-Like Peptide 1 - metabolism Heart attacks Hypertrophy, Left Ventricular - pathology Hypoglycemic Agents - therapeutic use In Vitro Techniques Kinases Mice Myocardial Infarction - drug therapy Myocardial Infarction - pathology Myocardium - metabolism Myocardium - pathology Myocytes, Cardiac - drug effects Myocytes, Cardiac - pathology Nitric oxide Organ Size - drug effects Peptides Phospholipases A2 - metabolism Prostaglandin-Endoperoxide Synthases - metabolism Protective Agents - therapeutic use Proteins Pyrazines - therapeutic use Rodents Sitagliptin Phosphate Thiazolidinediones - therapeutic use Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!